MRI contrast developer Epix Pharmaceuticals of Lexington, MA, has received approval from the U.S. Food and Drug Administration (FDA) to market its blood pool MR angiography contrast agent.
Vasovist is intended for use in evaluating aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. AIOD occurs when iliac arteries become narrowed or blocked, potentially preventing the sufficient transport of oxygen and blood throughout the body.
Vasovist becomes the first contrast agent to be approved for marketing in the U.S. for use with MR angiography. The agent is already approved for marketing in 34 countries outside the U.S.
Copyright © 2008 AuntMinnie.com